Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HRS-717 + HRS-4642 + SHR-1316
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Oral
01
Overview
HRS-717 + HRS-4642 + SHR-1316 (also referred to as HRS-7172 + HRS-4642 + SHR-1316) is an investigational combination regimen developed by Jiangsu Hengrui Pharmaceuticals for the treatment of advanced solid tumors, particularly advanced pancreatic cancer harboring RAS mutations or amplifications. The combination consists of three active components: HRS-7172, an orally active pan-RAS inhibitor; HRS-4642, an intravenously administered liposomal formulation of a selective KRAS G12D inhibitor; and SHR-1316 (adebrelimab), a humanized IgG4 monoclonal antibody targeting the immune checkpoint PD-L1. By simultaneously inhibiting oncogenic RAS/KRAS signaling and blocking the PD-1/PD-L1 immune checkpoint pathway, this combination is designed to overcome the immunosuppressive tumor microenvironment and enhance anti-tumor efficacy in RAS-mutated cancers.
- Other names
- HRS-717 + HRS-4642 + adebrelimabHRS-7172 + HRS-4642 + SHR-1316HRS-7172 + HRS-4642 + adebrelimabadebrelimab + HRS-4642 + HRS-717adebrelimab + HRS-4642 + HRS-7172
02
Targets
HRAS (H-Ras protein)CD274 (Programmed cell death protein 1 ligand 1)NRAS (Neuroblastoma RAS viral oncogene homolog)KRAS (Kirsten rat sarcoma viral oncogene homolog)
Beyond the preview
Go deeper on HRS-717 + HRS-4642 + SHR-1316.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HRS-717 + HRS-4642 + SHR-1316.